Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 253 for your search:
Drug:
oxaliplatin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase IV Study of the Relationship Between Residual Platinum Levels in the Blood and Persistent Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GERCOR-TAUROX
, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
2.
Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CHUL-BIO-COLON
, RECF0356, INCA-RECF0356, NCT00559676
3.
Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 74
Sponsor:
Other
Protocol IDs:
2009-03
, NCT00868569
4.
Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
2009-04
, NCT00874406
5.
Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
FRE-FNCLCC-ACCORD-11/0402
, EU-20512, NCT00112658
6.
Phase II/III Randomized Study of Fluorouracil, Cisplatin, and Radiotherapy Versus Gemcitabine Hydrochloride and Oxaliplatin in Patients With Unresectable, Nonmetastatic Cancer of the Biliary Tract
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FFCD-9902
, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
7.
Phase II/III Randomized Study of Radiochemotherapy Comprising the FOLFOX Regimen Versus Fluorouracil and Cisplatin (Herskovic Regimen) as First-Line Therapy in Patients With Inoperable Esophageal Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
FRE-FNCLCC- ACCORD-17/0707
, FRE-FNCLCC- ACCORD-17/0707, EU-20848, NCT00861094
8.
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
STX0206
, NCT00724503
9.
Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase:
Phase III, Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UKM-MRC-FOCUS3-CR12
, FOCUS 3 - CR12, EUDRACT-2008-008323-15, EU-20960, NCT00975897
10.
Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NSABP-R-04
, NCT00058474, CALGB-NSABP-R-04
11.
Phase III Randomized Study of Leucovorin Calcium and Fluorouracil With or Without Oxaliplatin Versus Capecitabine With or Without Oxaliplatin in Patients With Metastatic Colorectal Adenocarcinoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
NCRI-FOCUS2
, MRC-CR09, EU-20303, NCT00070213
12.
Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCCTG-N0147
, ECOG-N0147, N0147, NCT00079274
13.
Phase III Randomized Study of Bleomycin, Etoposide, and Cisplatin With or Without Dose-Dense Sequential Combination Chemotherapy in Patients With Poor Prognosis Stage II or III Non-Seminomatous Germ Cell Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 16
Sponsor:
Other
Protocol IDs:
FRE-FNCLCC-GETUG-13/0206
, EU-20502, NCT00104676
14.
Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer and at High Risk for Recurrence Based on Molecular Markers
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E5202
, E5202, NCT00217737
15.
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
75 and under
Sponsor:
Other
Protocol IDs:
FFCD 2000 – 05
, CET 815, NCT00126256
16.
Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX 4) Versus High-Dose Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX 7) Followed by Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Colorectal Cancer Metastatic to the Liver
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GERCOR-C02-1
, GERCOR-C02-1-MIROX, EU-20567, SANOFI-GERCOR-C02-1, NCT00268398
17.
Phase III Randomized Study of Adjuvant Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Cetuximab in Patients With Completely Resected Stage III Colon Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 74
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FFCD-PETACC-8
, EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811
18.
Phase III Randomized Study of Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (Modified FOLFOX) or Oxaliplatin and Capecitabine (XELOX) in Combination With Bevacizumab With Versus Without Erlotinib in Patients With Unresectable Metastatic Colorectal Adenocarcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GERCOR-C04-2
, EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824, GERCOR-DREAM- C04-2
19.
Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Arm III [Cetuximab and Bevacizumab in Combination With FOLFOX or FOLFIRI] Closed to Accrual as of 09/10/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-C80405
, C80405, SWOG-C80405, NCT00265850
20.
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CAO/ARO/AIO-04
, German Cancer Aid (no. 106759), NCT00349076
21.
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HEPATICA
, NCT00394992
22.
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
D8480C00051
, EUDRACT No 2006-001194-14, HORIZON II, NCT00399035
23.
Phase III Randomized Study of Adjuvant Chemotherapy Comprising Capecitabine and Oxaliplatin Versus Standard Follow-Up Care in Patients With Clear Margins After Complete Resection of Locally Advanced Rectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CRUK-CHRONICLE
, CRUK-BRD/05/132, EU-20679, ISRCTN59865116, CTA21106/0016/001, EUDRACT-2004-001484-21, NCT00427713
24.
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
LSO-OL006
, NCT00440310
25.
Phase III Randomized Study of Neoadjuvant and Adjuvant Combination Chemotherapy With Versus Without Cetuximab in Patients With Resectable Colorectal Liver Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
USCTU-4351
, EPOC, USCTU-EPOC, EUDRACT-2006-003121-82, ISRCTN22944367, EU-20732, NCT00482222
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
